A pharmacovigilance study of association between proton pump inhibitor and dementia event based on FDA adverse event reporting system data

Abstract Proton pump inhibitor (PPI) was widely used around the world. Studies suggested conflicting results between PPI treatment and dementia event. This study examined the association between six PPI agents and dementia event by mining the US FDA Adverse Event Reporting System (FAERS) database fr...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Bin Wu, Qiaozhi Hu, Fangyuan Tian, Fengbo Wu, Yuwen Li, Ting Xu
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/73f44cc4756845329c90ca0f5afa0d53
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:73f44cc4756845329c90ca0f5afa0d53
record_format	dspace
spelling	oai:doaj.org-article:73f44cc4756845329c90ca0f5afa0d532021-12-02T16:51:14ZA pharmacovigilance study of association between proton pump inhibitor and dementia event based on FDA adverse event reporting system data10.1038/s41598-021-90108-72045-2322https://doaj.org/article/73f44cc4756845329c90ca0f5afa0d532021-05-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-90108-7https://doaj.org/toc/2045-2322Abstract Proton pump inhibitor (PPI) was widely used around the world. Studies suggested conflicting results between PPI treatment and dementia event. This study examined the association between six PPI agents and dementia event by mining the US FDA Adverse Event Reporting System (FAERS) database from 2004 to 2020. We employed proportional reporting ratio (PRR) and information element (IC) methods to detect the signals of dementia relevant to PPI. We also analyzed characteristics of PPI and positive control reports, compared dementia event between long- and short-duration of PPI treatment. Finally, we identified 2396 dementia cases with PPI treatment. We did not detect significant signal between PPI and dementia event: PRR = 0.98, 95%CI 0.94 to 1.02, IC = −0.03, 95%CI − 0.17 to 0.10, even in gastroesophageal reflux disease cases: PRR = 0.65, 95%CI 0.59 to 0.72, IC = −0.62, 95%CI − 0.97 to − 0.27. No significant differences of dementia event were detected between long- and short- duration groups, the OR (95%CI) of the 3 years, 5 years and 10 years comparison were 0.70 (0.48 to 1.02), 0.72 (0.45 to 1.15) and 1.65 (0.75 to 3.63), respectively. Based on the current FAERS data mining, we discovered no association between PPI use and dementia event, even in long-term PPI therapy case.Bin WuQiaozhi HuFangyuan TianFengbo WuYuwen LiTing XuNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Bin Wu Qiaozhi Hu Fangyuan Tian Fengbo Wu Yuwen Li Ting Xu A pharmacovigilance study of association between proton pump inhibitor and dementia event based on FDA adverse event reporting system data
description	Abstract Proton pump inhibitor (PPI) was widely used around the world. Studies suggested conflicting results between PPI treatment and dementia event. This study examined the association between six PPI agents and dementia event by mining the US FDA Adverse Event Reporting System (FAERS) database from 2004 to 2020. We employed proportional reporting ratio (PRR) and information element (IC) methods to detect the signals of dementia relevant to PPI. We also analyzed characteristics of PPI and positive control reports, compared dementia event between long- and short-duration of PPI treatment. Finally, we identified 2396 dementia cases with PPI treatment. We did not detect significant signal between PPI and dementia event: PRR = 0.98, 95%CI 0.94 to 1.02, IC = −0.03, 95%CI − 0.17 to 0.10, even in gastroesophageal reflux disease cases: PRR = 0.65, 95%CI 0.59 to 0.72, IC = −0.62, 95%CI − 0.97 to − 0.27. No significant differences of dementia event were detected between long- and short- duration groups, the OR (95%CI) of the 3 years, 5 years and 10 years comparison were 0.70 (0.48 to 1.02), 0.72 (0.45 to 1.15) and 1.65 (0.75 to 3.63), respectively. Based on the current FAERS data mining, we discovered no association between PPI use and dementia event, even in long-term PPI therapy case.
format	article
author	Bin Wu Qiaozhi Hu Fangyuan Tian Fengbo Wu Yuwen Li Ting Xu
author_facet	Bin Wu Qiaozhi Hu Fangyuan Tian Fengbo Wu Yuwen Li Ting Xu
author_sort	Bin Wu
title	A pharmacovigilance study of association between proton pump inhibitor and dementia event based on FDA adverse event reporting system data
title_short	A pharmacovigilance study of association between proton pump inhibitor and dementia event based on FDA adverse event reporting system data
title_full	A pharmacovigilance study of association between proton pump inhibitor and dementia event based on FDA adverse event reporting system data
title_fullStr	A pharmacovigilance study of association between proton pump inhibitor and dementia event based on FDA adverse event reporting system data
title_full_unstemmed	A pharmacovigilance study of association between proton pump inhibitor and dementia event based on FDA adverse event reporting system data
title_sort	pharmacovigilance study of association between proton pump inhibitor and dementia event based on fda adverse event reporting system data
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/73f44cc4756845329c90ca0f5afa0d53
work_keys_str_mv	AT binwu apharmacovigilancestudyofassociationbetweenprotonpumpinhibitoranddementiaeventbasedonfdaadverseeventreportingsystemdata AT qiaozhihu apharmacovigilancestudyofassociationbetweenprotonpumpinhibitoranddementiaeventbasedonfdaadverseeventreportingsystemdata AT fangyuantian apharmacovigilancestudyofassociationbetweenprotonpumpinhibitoranddementiaeventbasedonfdaadverseeventreportingsystemdata AT fengbowu apharmacovigilancestudyofassociationbetweenprotonpumpinhibitoranddementiaeventbasedonfdaadverseeventreportingsystemdata AT yuwenli apharmacovigilancestudyofassociationbetweenprotonpumpinhibitoranddementiaeventbasedonfdaadverseeventreportingsystemdata AT tingxu apharmacovigilancestudyofassociationbetweenprotonpumpinhibitoranddementiaeventbasedonfdaadverseeventreportingsystemdata AT binwu pharmacovigilancestudyofassociationbetweenprotonpumpinhibitoranddementiaeventbasedonfdaadverseeventreportingsystemdata AT qiaozhihu pharmacovigilancestudyofassociationbetweenprotonpumpinhibitoranddementiaeventbasedonfdaadverseeventreportingsystemdata AT fangyuantian pharmacovigilancestudyofassociationbetweenprotonpumpinhibitoranddementiaeventbasedonfdaadverseeventreportingsystemdata AT fengbowu pharmacovigilancestudyofassociationbetweenprotonpumpinhibitoranddementiaeventbasedonfdaadverseeventreportingsystemdata AT yuwenli pharmacovigilancestudyofassociationbetweenprotonpumpinhibitoranddementiaeventbasedonfdaadverseeventreportingsystemdata AT tingxu pharmacovigilancestudyofassociationbetweenprotonpumpinhibitoranddementiaeventbasedonfdaadverseeventreportingsystemdata
_version_	1718382984812298240

A pharmacovigilance study of association between proton pump inhibitor and dementia event based on FDA adverse event reporting system data

Ejemplares similares